Daiichi Sankyo’s Edoxaban Could Find Role In Treating Sickest Patients
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Firm’s Factor Xa inhibitor demonstrates equal efficacy to warfarin with lower overall clinically relevant bleeding in a Phase III study; drug works well even in patients with right ventricular dysfunction, a sign of more serious pulmonary embolism.